Navigation Links
Rigel to Present at Keystone Symposia Conference
Date:1/23/2009

SOUTH SAN FRANCISCO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting at the Keystone Symposia conference on Multiple Sclerosis taking place this week in Santa Fe, New Mexico.

Presentation Date: Sunday, January 25, 2009

Time: 2:30 - 4:30pm

Session: Workshop 2: New Therapeutic Approaches to MS

Presentation Title: The orally bioavailable Protein Kinase C Inhibitor RGE-80 can abrogate EAE disease induction and ameliorates disease in a therapeutic setting

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
2. Rigel to Present at the Piper Jaffray Annual Health Care Conference
3. Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
4. Rigel to Webcast Investor Update on October 27, 2008
5. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
6. Rigel to Present at Collins Stewart Growth Conference
7. Rigel Announces First Quarter 2008 Financial Results
8. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
9. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
10. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
11. Rigel Announces Offering of 4,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo reveals ... of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. Easily ... from a variety of flip book animations. In Addition, users can modify each preset ...
(Date:12/7/2016)... ... December 07, 2016 , ... Bioelectronic ... Plus for consumers and healthcare professionals to manage chronic and acute pain. ... treatment modalities available in a single device. The announcement is part of ...
(Date:12/7/2016)... ... 2016 , ... “The Road To Restoration”: an informative and enlightening book ... a week showing of hands. “The Road To Restoration” is the creation of published ... with the brass ring that you could reach out for, and grab, on the ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons ... will inspire the reader to be aware of God's direction in their lives. “Walking ... Sanford Smith, retired teacher and active church leader. , Sanford says, “I ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... Dec. 6, 2016  Viking Therapeutics, Inc. ("Viking") ... company focused on the development of novel therapies ... the U.S. Food and Drug Administration (FDA) has ... treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a ... that selectively regulates the expression of genes believed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
Breaking Medicine Technology: